Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BSTG NASDAQ:BTCY NASDAQ:LUNG NASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTGBiostage$4.45$4.45$4.45▼$4.45$61.78M-1.021,847 shsN/ABTCYBiotricity$0.67-1.5%$0.51$0.19▼$0.83$16.72M1.1937,333 shs10,519 shsLUNGPulmonx$1.58-0.6%$2.12$1.47▼$9.37$64.38M0.43452,629 shs248,888 shsTELATELA Bio$1.58$1.80$0.86▼$3.26$62.59M0.84166,964 shs133,298 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTGBiostage0.00%0.00%0.00%0.00%0.00%BTCYBiotricity-6.04%-4.03%+8.09%+41.96%+75.17%LUNGPulmonx-6.47%-6.47%+1.92%-41.33%-80.87%TELATELA Bio0.00%-2.47%0.00%+5.33%-40.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSTGBiostage$4.45$4.45$4.45▼$4.45$61.78M-1.021,847 shsN/ABTCYBiotricity$0.67-1.5%$0.51$0.19▼$0.83$16.72M1.1937,333 shs10,519 shsLUNGPulmonx$1.58-0.6%$2.12$1.47▼$9.37$64.38M0.43452,629 shs248,888 shsTELATELA Bio$1.58$1.80$0.86▼$3.26$62.59M0.84166,964 shs133,298 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSTGBiostage0.00%0.00%0.00%0.00%0.00%BTCYBiotricity-6.04%-4.03%+8.09%+41.96%+75.17%LUNGPulmonx-6.47%-6.47%+1.92%-41.33%-80.87%TELATELA Bio0.00%-2.47%0.00%+5.33%-40.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSTGBiostage 0.00N/AN/AN/ABTCYBiotricity 2.00HoldN/AN/ALUNGPulmonx 2.56Moderate Buy$7.66385.08% UpsideTELATELA Bio 2.50Moderate Buy$4.50184.81% UpsideCurrent Analyst Ratings BreakdownLatest BTCY, LUNG, BSTG, and TELA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.008/1/2025LUNGPulmonxWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $3.007/31/2025LUNGPulmonxLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.007/31/2025LUNGPulmonxStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $5.007/31/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $16.007/31/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$9.00 ➝ $2.50(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSTGBiostageN/AN/AN/AN/A($0.26) per shareN/ABTCYBiotricity$12.06M1.39N/AN/A($1.30) per share-0.52LUNGPulmonx$90.55M0.71N/AN/A$2.17 per share0.73TELATELA Bio$75.32M0.83N/AN/A$0.72 per share2.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSTGBiostage-$6.07M-$0.58N/A∞N/AN/AN/A-174.43%N/ABTCYBiotricity-$14.09M-$0.21N/A∞N/A-80.42%N/A-188.47%11/13/2025 (Estimated)LUNGPulmonx-$56.39M-$1.43N/AN/AN/A-62.88%-69.76%-36.26%10/29/2025 (Estimated)TELATELA Bio-$37.84M-$1.12N/AN/AN/A-54.12%-329.48%-57.34%11/6/2025 (Estimated)Latest BTCY, LUNG, BSTG, and TELA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025TELATELA Bio-$0.18-$0.22-$0.04-$0.22$20.67 million$20.20 million7/30/2025Q2 2025LUNGPulmonx-$0.40-$0.38+$0.02-$0.38$23.46 million$23.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSTGBiostageN/AN/AN/AN/AN/ABTCYBiotricityN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSTGBiostageN/A2.732.73BTCYBiotricityN/A0.230.10LUNGPulmonx0.545.354.63TELATELA Bio4.143.192.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSTGBiostageN/ABTCYBiotricity3.89%LUNGPulmonx91.04%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipBSTGBiostage15.30%BTCYBiotricity10.10%LUNGPulmonx6.80%TELATELA Bio4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSTGBiostage713.88 million11.76 millionNot OptionableBTCYBiotricity4024.91 million22.08 millionOptionableLUNGPulmonx25040.75 million37.98 millionOptionableTELATELA Bio12039.62 million37.75 millionOptionableBTCY, LUNG, BSTG, and TELA HeadlinesRecent News About These CompaniesTELA Bio’s Earnings Call Highlights Robust GrowthSeptember 14 at 1:45 PM | theglobeandmail.com200,000 Shares in TELA Bio, Inc. $TELA Acquired by Paradigm Capital Management Inc. NYSeptember 2, 2025 | marketbeat.com747,410 Shares in TELA Bio, Inc. $TELA Acquired by Velan Capital Investment Management LPAugust 31, 2025 | marketbeat.comStonepine Capital Management LLC Has $2.51 Million Stake in TELA Bio, Inc. $TELAAugust 26, 2025 | marketbeat.comTELA Bio (NASDAQ:TELA) Shares Down 2.9% - Here's What HappenedAugust 23, 2025 | marketbeat.comAroa Biosurgery Reports Strong Growth and Expands Product Range Amid Market ChallengesAugust 20, 2025 | msn.comTela Bio reports Q2 EPS (22c), consensus (19c)August 13, 2025 | msn.comTela Bio backs FY25 revenue view $85M-$88M, consensus $86.05MAugust 12, 2025 | msn.comTela Bio reiterates $85M–$88M 2025 revenue target as international expansion acceleratesAugust 12, 2025 | msn.comTELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2025 | zacks.comTELA Bio, Inc. (TELA) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comTELA Bio Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | globenewswire.comTELA Bio Inc (TELA) Q2 2025 Earnings Report Preview: What To ExpectAugust 10, 2025 | finance.yahoo.comTELA Bio Awards Inducement Equity Grants to New EmployeesAugust 10, 2025 | msn.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 | globenewswire.comTELA Bio to Participate in the Canaccord Genuity 45th Annual Growth ConferenceJuly 23, 2025 | globenewswire.comTELA Bio to Announce Second Quarter 2025 Financial ResultsJuly 21, 2025 | globenewswire.comTELA Bio, Inc. (TELA) Latest Stock News & Headlines - Yahoo FinanceJuly 19, 2025 | finance.yahoo.comBreakeven On The Horizon For TELA Bio, Inc. (NASDAQ:TELA)July 3, 2025 | finance.yahoo.comTELA Bio Welcomes Jim Hagen with Strategic Equity GrantJune 9, 2025 | msn.comTELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 7, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is ExpectedBy Thomas Hughes | September 4, 20252 Falling Knives That Might Be Worth CatchingBy Sam Quirke | September 16, 2025BTCY, LUNG, BSTG, and TELA Company DescriptionsBiostage OTCMKTS:BSTG$4.45 0.00 (0.00%) As of 07/24/2023Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.Biotricity NASDAQ:BTCY$0.67 -0.01 (-1.53%) As of 01:52 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Pulmonx NASDAQ:LUNG$1.58 -0.01 (-0.63%) Closing price 04:00 PM EasternExtended Trading$1.59 +0.01 (+0.63%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.TELA Bio NASDAQ:TELA$1.58 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.32%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
